Abzena

In a recent article with PharmTech entitled "Navigating the Complexities of Drug Formulation," Gary Watts, Senior Manager and Head of Formulation at Abzena, delves into the intricate process of transforming bioactive molecules into effective, stable, and patient-friendly medications.   Gary explores how early detection of drug instabilities and proactive formulation strategies are essential to avoid costly setbacks later in development. He highlights the importance of understanding drug properties, enhancing solubility and stability, and tailoring delivery methods to meet patient-centric needs.   Discover how these formulation advancements not only enhance drug efficacy and patient compliance but also streamline development processes—reducing costs and accelerating time to market.   Read the full article here: https://lnkd.in/ebMbPFCn   #Formulation #DrugDevelopment #CDMO #CRO #Biologics

At Abzena, effective project management is crucial for delivering successful biopharmaceutical drug development programs. Our latest blog features a colleague spotlight on Darren Bird, one of our dedicated project managers who plays a vital role in coordinating complex projects across departments and global sites.   Discover how Darren's expertise in project management enhances collaboration across our teams and partners. His insights shed light on his career path into the field and how strategic project management contributes to timely delivery and high-quality outcomes for our customers.   Read more about Darren's contributions and the impact of project management at Abzena: https://lnkd.in/eaVDG3jK   #ProjectManagement #DrugDevelopment #Spotlight #CDMO #CRO #AbzenaCareers

Heading to World ADC San Diego next month? Our team of experts—Dr. Stephen Verespy, Dr. Francisco Velazquez, Matthew Stober, Sudha Krishnan, Zoe Yi Zhang, Craig Magee, Ph.D., 🧬 Greg Downs, Barbara Arnold, and Jonny Cruickshank — will be at booth #401 ready to discuss your ADC development challenges and share how our fully integrated CDMO+CRO capabilities can help you overcome them faster and with greater success.   Don't miss our insightful presentations: -Tuesday, November 5 at 12:30 PM – "Development of a Site-Specific and Versatile Conjugation Approach Based on Bacterial Transglutaminase and the Diels-Alder Cycloaddition Reaction. Utilization of Maleimides as Dienophiles for Generation of ADCs." by Dr. Francisco Velasquez -Wednesday, November 6 at 11:30 AM – "Leveraging ADC Development Knowledge to Overcome Challenges and Build Opportunities for the Efficient Scale-Up and Development of Novel AOCs" by Dr. Stephen Verespy From our advanced conjugation technologies to our comprehensive end-to-end development and cGMP manufacturing capabilities, our team welcomes the opportunity to discuss how we can help de-risk and streamline your ADC programs from discovery to commercial launch.   Click here to schedule a meeting with our team at World ADC San Diego: https://lnkd.in/eTQ2MEHS   #ADCDevelopment #Bioconjugation #DrugDevelopment #CDMO #CRO #Biopharma #WorldADC2024

Utilizing bioassays early on in the development process can provide valuable insights that help to identify risks earlier in the drug development process so that developers can ‘start smart, and finish fast.’   At Abzena, we have decades of expertise in delivering a comprehensive range of analytics and bioassays that help our customers streamline and de-risk their complex biologic and ADC development programs. From discovery-themed assay applications that support target validation and hit-to-lead screening through design, development, and manufacturing, our full suite of analytical assessments provide you with the necessary data needed to make informed decisions.   Discover how our experienced team can de-risk your biologic or bioconjugate program with our extensive bioassays & immunogenicity assessments by clicking here:  https://lnkd.in/e5kp7XGM   #BiologicsDevelopment #Bioassays #Analytics #CDMO #DrugDevelopment #CRO

Day 2 is in full swing at #AAPS in Salt Lake City! Abzena’s experts welcome you to swing by our booth #2711 to discuss your biopharmaceutical program and hear how our fully integrated capabilities can de-risk & rapidly move your program from early discovery through commercial. Our unique solutions help customers achieve greater success, faster: -AbZelectPRO, our cell line development platform reduces timelines by 25% and achieves 8g/L in high-performing titres -EpiScreen 2.0, our enhanced bioassay platform that predicts & evaluates potential risks of preclinical immunogenicity in protein, antibody, and gene therapy therapeutics -LabZient- our analytical platform that delivers rapid, accurate data that expedites the path to IND for Antibodies Click here to schedule a meeting with our team at the event to learn more: https://lnkd.in/eR29rDSE Campbell Bunce PhD MBA, Parviz A. Shamlou, Zoe Yi Zhang, Yang Wang-Smalley, Julie Grace, and Danielle Mello

In our most recent scientific poster presented this week at AAPS PharmSci360, we discuss a "Platform Approach for Identifying the Most Functional and Developable Bispecific T Cell Engager."   The purpose of this study was to evaluate a platform for optimal bispecific design and selection using two functionalities, a cancer target – anti CD19, and a T cell recruiter – anti-CD. Key learnings from this project include the importance of gaining high purity from simple purifications and the potential problems with reformatting into a single chain Fv format.   Click here to access the poster: https://lnkd.in/eHiMYg9D   #Bispecifics #CDMO #CRO #scientificposter #AAPS #DrugDevelopment

Join Dr. Petra Dieterich, DPhil, MBA, Abzena's SVP & Scientific Leader, for an insightful talk on Antibody-Drug Conjugates (ADCs) development and manufacturing during the Outsourced Pharma Capacity Update on October 21st. This talk will dive into the role CDMOs play in ADC advancements and how these groundbreaking therapies are transforming oncology.   Gain insights on collaborating with CDMO partners, explore available capacity, and learn how Abzena’s expertise can support your therapeutic pipeline. Register here: https://lnkd.in/eCGZupHN #ADCs #CDMO #OncologyAdvancements #BiologicsDevelopment #CRO #Biopharma

Early-stage bioconjugate development requires deep expertise and technical knowhow to ensure lead candidates are safe, functional, and manufacturable. Without the right approach, costly setbacks can arise, impacting timelines and clinical outcomes.   At Abzena, we guide you through this complexity with a comprehensive, de-risked approach to bioconjugate and ADC development. Having worked with hundreds of bioconjugate candidates, we leverage our decades of experience to help you create a matrix of candidates, applying the right bioassays and analytics to assess their developability early on to ensure the best success rate.   Discover our robust and comprehensive suite of development capabilities for ADCs, AOCs and more, by visiting: https://lnkd.in/eWExj5P5   #ADCDevelopment #Bioconjugation #Biopharma #DrugDevelopment #CDMO #CRO #Biotechnology

Headed to AAPS PharmSci360 next week? Our team of experts, Dr Campbell Bunce PhD MBA, Parviz A. Shamlou, Zoe Yi Zhang, Julie Grace and Yang Wang-Smalley, will be there in booth #2711 to discuss your biologic's drug development challenges and share how our fully integrated CDMO+CRO capabilities can help you overcome them faster and with greater success.     Also, make sure not to miss our poster sessions on Monday & Wednesday: -Monday, October 21 at 3:30 PM – ‘Platform Approach for Identifying the Most Functional and Developable Bispecific T Cell Engager’ -Wednesday, October 23 at 12:30 PM – ‘EpiScreen® 2.0 Time Course Assay: A Sensitive and Data Rich Tool for Pre-Clinical Immunogenicity Testing of Biologics’ From our recently enhanced AbZelectPRO cell line development platform, offering quicker doubling times and 8g/L in high-performing titres to our comprehensive immunogenicity assessment platform, EpiScreen 2.0, our team welcomes the opportunity to discuss how our end-to-end design, development and cGMP manufacturing capabilities can help de-risk and streamline your biopharmaceutical program from discovery through to commercial product launch. Click here to schedule a meeting with our team at AAPS: https://lnkd.in/eR29rDSE   #PharmaSci360 #Bioconjugation #DrugDevelopment #CDMO #CRO #Biologics

Abzena’s Sr. Director of Bioconjugation Chemistry, Nicolas Camper, recently shared his expertise ahead of #CPHI Milan last week in an insightful interview with Pharmaceutical Technology focusing on the latest advancements in #Bioconjugation and Linker Technologies. Nicolas delves into the significant progress being made in #ADC development and manufacturing, highlighting how these innovations are shaping the future of biopharmaceuticals.   This discussion underscores Abzena’s commitment to driving excellence in bioconjugation chemistry and supporting our partners in advancing their innovative drug development pipelines with cutting-edge solutions. Access the video interview here: https://lnkd.in/gjS7i9Cf   #ADC #CRO #DrugDevelopment #Biotechnology #CPHIMilan2024 #Innovation